Composition for Treating Prostate Cancer
US-2016375091-A1 · Dec 29, 2016 · US
Composition for preventing or treating cachexia
US9907837B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9907837-B2 |
| Application number | US-201314400299-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 10, 2013 |
| Priority date | May 11, 2012 |
| Publication date | Mar 6, 2018 |
| Grant date | Mar 6, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to composition for preventing or treating cachexia, and more specifically, to a composition for preventing or treating cachexia containing a peptide derived from a telomerase. The composition for preventing or treating cachexia, according to present invention, has the advantages of improving symptoms of cachexia, such as weight loss, anemia, edema, and loss of appetite, and has few side effects.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating cachexia caused by rheumatoid arthritis comprising administering to a subject in need thereof the isolated peptide of SEQ ID NO: 1. 2. The method according to claim 1 , wherein the peptide is administered in a single dose at a concentration of 0.001 to 1 ng/kg. 3. The method according to claim 1 , wherein the peptide is administered in a single dose at a concentration of 0.01 to 0.4 ng/kg. 4. The method according to claim 1 , wherein the peptide is administered 1 to 3 times a day. 5. The method of claim 1 , wherein the peptide is administered at a daily dose of 0.001 to 1 ng/kg. 6. The method of claim 5 , wherein the peptide is administered 1 to 3 times daily. 7. A method for treating cachexia caused by rheumatoid arthritis comprising administering to a subject in need thereof a composition comprising the isolated peptide of SEQ ID NO: 1. 8. The method of claim 7 , wherein the composition is administered through oral, rectal, transdermal, intravenous, intramuscular, intraperitoneal, intramedullary, epidural, or subcutaneous routes. 9. The method of claim 7 , wherein the composition comprises 0.1 μg/mg to 1 mg/mg of isolated peptide. 10. The method of claim 7 , wherein the peptide is administered in a single dose at a concentration of 0.001 to 1 ng/kg. 11. The method of claim 7 , wherein the peptide is administered in a single dose at a concentration of 0.01 to 0.4 ng/kg. 12. The method of claim 7 , wherein the peptide is administered 1 to 3 times a day. 13. The method of claim 12 , wherein the peptide is administered at a daily dose of 0.001 to 1 ng/kg. 14. The method of claim 13 , wherein the peptide is administered 1 to 3 times daily. 15. The method of claim 7 , wherein the composition is a pharmaceutical composition. 16. The method of claim 15 , wherein the composition is formulated for injection.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title
Antibacterial agents · CPC title
Antineoplastic agents · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9907837B2 cover?
- The present invention relates to composition for preventing or treating cachexia, and more specifically, to a composition for preventing or treating cachexia containing a peptide derived from a telomerase. The composition for preventing or treating cachexia, according to present invention, has the advantages of improving symptoms of cachexia, such as weight loss, anemia, edema, and loss of appe…
- Who is the assignee on this patent?
- Gemvax & Kael Co Ltd, Kim Sang Jae
- What technology area does this patent fall under?
- Primary CPC classification A61K38/10. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 11 related publications on this page (citations in our corpus or others sharing the same primary CPC).